Vanessa Bolejack
Overview
Explore the profile of Vanessa Bolejack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
5881
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Attia S, Bolejack V, Ganjoo K, George S, Agulnik M, Rushing D, et al.
Cancer Med
. 2022 Aug;
12(2):1532-1539.
PMID: 35950293
Background: Regorafenib is one of several FDA-approved cancer therapies targeting multiple tyrosine kinases. However, there are few subtype-specific data regarding kinase inhibitor activity in sarcomas. We report results of a...
2.
Denmeade S, Wang H, Agarwal N, Smith D, Schweizer M, Stein M, et al.
J Clin Oncol
. 2021 Feb;
39(12):1371-1382.
PMID: 33617303
Purpose: Prostate cancer (PCa) becomes resistant to androgen ablation through adaptive upregulation of the androgen receptor in response to the low-testosterone microenvironment. Bipolar androgen therapy (BAT), defined as rapid cycling...
3.
Petitprez F, De Reynies A, Keung E, Chen T, Sun C, Calderaro J, et al.
Nature
. 2020 Jan;
577(7791):556-560.
PMID: 31942077
Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50 histological subtypes. The clinical presentation of patients with different subtypes is often atypical, and responses to therapies such...
4.
Keung E, Burgess M, Salazar R, Parra E, Rodrigues-Canales J, Bolejack V, et al.
Clin Cancer Res
. 2020 Jan;
26(6):1258-1266.
PMID: 31900276
Purpose: We recently reported a 17.5% objective RECIST 1.1 response rate in a phase II study of pembrolizumab in patients with advanced sarcoma (SARC028). The majority of responses occurred in...
5.
Davis L, Bolejack V, Ryan C, Ganjoo K, Loggers E, Chawla S, et al.
J Clin Oncol
. 2019 Apr;
37(16):1424-1431.
PMID: 31013172
Purpose: SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma subtypes, including advanced osteosarcoma. We hypothesized that regorafenib would improve progression-free survival (PFS) in...
6.
Schuetze S, Bolejack V, Thomas D, von Mehren M, Patel S, Samuels B, et al.
JAMA Oncol
. 2018 May;
4(6):814-820.
PMID: 29710216
Importance: Gastrointestinal stromal tumors (GISTs) are life-threatening when metastatic or not amenable to surgical removal. In a few patients with advanced GISTs refractory to imatinib mesylate, treatment with sunitinib malate...
7.
Tawbi H, Bolejack V, Burgess M, Schuetze S
Lancet Oncol
. 2018 Jan;
19(1):e7.
PMID: 29304367
No abstract available.
8.
Ramanathan R, Weiss G, Posner R, Rajeshkumar N, Jameson G, Aziz M, et al.
J Gastrointest Oncol
. 2018 Jan;
8(6):925-935.
PMID: 29299351
Background: The choice of a regimen in metastatic pancreatic cancer patients following progression on 1st line therapy is empiric and outcomes are unsatisfactory. This phase II study was performed to...
9.
Tawbi H, Burgess M, Bolejack V, Van Tine B, Schuetze S, Hu J, et al.
Lancet Oncol
. 2017 Oct;
18(11):1493-1501.
PMID: 28988646
Background: Patients with advanced sarcomas have a poor prognosis and few treatment options that improve overall survival. Chemotherapy and targeted therapies offer short-lived disease control. We assessed pembrolizumab, an anti-PD-1...
10.
Chansky K, Detterbeck F, Nicholson A, Rusch V, Vallieres E, Groome P, et al.
J Thorac Oncol
. 2017 May;
12(7):1109-1121.
PMID: 28461257
Introduction: Revisions to the TNM stage classifications for lung cancer, informed by the international database (N = 94,708) of the International Association for the Study of Lung Cancer (IASLC) Staging...